CSF3 and diffuse large B-cell lymphoma: Compared to a previous study reported in China, our data presented a significantly improved 5-year OS rate, which may attributed to the widespread use of rituximab, adoption of supportive therapy after chemotherapy, such as application of granulocyte colony-stimulating factor (G-CSF), and patient education, all together contributed to improve the survival of patients with DLBCL.